J. Casal

发表

Gemcitabine and cisplatin for advanced non-small cell lung cancer (NSCLC)

C. Grande, J. Casal, M. Caeiro, 1997 .

Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

C. Jara, E. Ciruelos, J. Baena, 2015, Clinical and Translational Oncology.

Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment

C. Grande, J. Casal, M. Villanueva, 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): A phase II multicenter exploratory study—NADIM study-SLCG.

B. Massuti, V. Calvo, D. Rodríguez-Abreu, 2018 .

Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group.

Jorge García, L. Santomé, M. Lázaro, 2022, Cancer treatment and research communications.

Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

J. Bosch-Barrera, B. Massuti, V. Calvo, 2022, BMC cancer.

Cancer Management and Research Dovepress Egfr Testing and Clinical Management of Advanced Nsclc: a Galician Lung Cancer Group Study (ggcp 048-10)

I. Abdulkader, L. Santomé, M. Lázaro, 2022 .

Interleukin-2 for the treatment of solid tumors other than melanoma and renal cell carcinoma

Joaquin Casal, C. Grande, Carlos Grande, 2006, Anti-cancer drugs.

Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group.

M. Lázaro, S. V. Estévez, L. León, 2003, Lung cancer.

First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

L. Santomé, M. Lázaro, L. León, 2012, Expert opinion on pharmacotherapy.

Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

J. Bosch-Barrera, B. Massuti, M. Provencio, 2021, BMC cancer.

Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: review of patient profile

L. Santomé, M. Lázaro, J. Fírvida, 2014, Anti-cancer drugs.

Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

E. Gallardo, M. Salgado, R. López, 2015, Cancer Chemotherapy and Pharmacology.

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

M. Ramos, S. Morales, A. Oltra, 2007, Cancer Chemotherapy and Pharmacology.

Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: results of a large, multicentre phase II study

M. Ramos, S. Morales, A. Oltra, 2003, Cancer Chemotherapy and Pharmacology.

Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study.

M. Lázaro, V. Giner, Ó. Juan, 2014, Anticancer research.

Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02)

M. Lázaro, M. Ramos, M. Salgado, 2007, Anti-cancer drugs.

Cancer Management and Research Dovepress Egfr Testing and Clinical Management of Advanced Nsclc: a Galician Lung Cancer Group Study (ggcp 048-10)

I. Abdulkader, L. Santomé, M. Lázaro, 2022 .

Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study

R. López-López, J. Tisaire, M. Constenla, 2007, Cancer Chemotherapy and Pharmacology.

PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement

N. Reguart, J. Zugazagoitia, M. Cobo, 2023, Journal of clinical medicine.

Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer.

E. Gallardo, C. Grande, S. Candamio, 2013, Journal of geriatric oncology.